SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation

Journal of the American Society of Nephrology

Volumn 20, Issue 12, 2009, Pages 2546-2555

  Toyohara, Takafumi ^a   Suzuki, Takehiro ^a   Morimoto, Ryo ^a   Akiyama, Yasutoshi ^a   Souma, Tomokazu ^a   Shiwaku, Hiromi O ^a   Takeuchi, Yoichi ^a   Mishima, Eikan ^a   Abe, Michiaki ^a   Tanemoto, Masayuki ^a   Masuda, Satohiro ^b   Kawano, Hiroaki ^c   Maemura, Koji ^c   Nakayama, Masaaki ^a   Sato, Hiroshi ^a   Mikkaichi, Tsuyoshi ^d   Yamaguchi, Hiroaki ^d   Fukui, Shigefumi ^a   Fukumoto, Yoshihiro ^a   Shimokawa, Hiroaki ^a   Inui, Ken Ichi ^b   Terasaki, Tetsuya ^e   Goto, Junichi ^d   Ito, Sadayoshi ^a   Hishinuma, Takanori ^e   Rubera, Isabelle ^f   Tauc, Michel ^f   Fujii Kuriyama, Yoshiaki ^g   Yabuuchi, Hikaru ^h   Moriyama, Yoshinori ⁱ   Soga, Tomoyoshi ^j   Abe, Takaaki ^a,e   more..

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

^e TOHOKU UNIVERSITY   (Japan)

^f CNRS   (France)

^g UNIVERSITY OF TSUKUBA   (Japan)

^h GenoMembrane Inc   (Japan)

ⁱ OKAYAMA UNIVERSITY   (Japan)

^j KEIO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACONITIC ACID; AROMATIC HYDROCARBON RECEPTOR; ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; GUANIDINOSUCCINIC ACID; MEVINOLIN; N(G),N(G) DIMETHYLARGININE; ORGANIC ANION TRANSPORTER; PITAVASTATIN; PRAVASTATIN; PROTEIN SLCO4C1; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CARDIOMEGALY; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HYPERTENSION; KIDNEY CLEARANCE; KIDNEY FAILURE; LOW DRUG DOSE; NEPHRITIS; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RAT; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 72049086464     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009070696     Document Type: Article

References (44)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004 (Pubitemid 39268908)
2. Kielstein JT, Zoccali C: Asymmetric dimethylarginine: A novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 17: 609-615, 2008
3. Marescau B, Nagels G, Possemiers I, De Broe ME, Becaus I, Billiouw JM, Lornoy W, De Deyn PP: Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 46: 1024-1031, 1997 (Pubitemid 27371819)
4. Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity? Pediatr Nephrol 23: 1211-1221, 2008
5. Torremans A, Marescau B, Kranzlin B, Gretz N, Billiouw JM, Vanholder R, De Smet R, Bouwman K, Brouns R, De Deyn PP: Biochemical validation of a rat model for polycystic kidney disease: Comparison of guanidino compound profile with the human condition. Kidney Int 69: 2003-2012, 2006 (Pubitemid 43924264)
6. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62: 339-345, 2002 (Pubitemid 34754080)
7. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: The Mild to Moderate Kidney Disease Study. J AmSoc Nephrol 16: 2456-2461, 2005 (Pubitemid 41725064)
8. Sanaka T, Akizawa T, Koide K, Koshikawa S: Protective effect of an oral adsorbent on renal function in chronic renal failure: Determinants of its efficacy in diabetic nephropathy. Ther Apher Dial 8: 232-240, 2004 (Pubitemid 38900430)
9. Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T: Effects of oral adsorbent AST-120 on the progression of chronic renal failure: A randomized controlled study. Kidney Int Suppl 63: S188-S190, 1997 (Pubitemid 28020467)
10. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A 101: 3569-3574, 2004
11. Rubera I, Poujeol C, Bertin G, Hasseine L, Counillon L, Poujeol P, Tauc M: Specific Cre/Lox recombination in the mouse proximal tubule. J Am Soc Nephrol 15: 2050-2056, 2004 (Pubitemid 39031344)
12. Silverstein DM: Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr Nephrol 24: 1445-1452, 2008
13. Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, Nishioka T: Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2: 488-494, 2003 (Pubitemid 37376843)
14. Baylis C: Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2: 209-220, 2006 (Pubitemid 43787287)
15. Levillain O, Marescau B, Possemiers I, Al Banchaabouchi M, De Deyn PP: Influence of 72% injury in one kidney on several organs involved in guanidino compound metabolism: A time course study. Pflugers Arch 442: 558-569, 2001 (Pubitemid 32673323)
16. Saffran M, Prado JL: Inhibition of aconitase by trans-aconitate. J Biol Chem 180: 1301-1309, 1949
17. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, Luno J: Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl S4-S9, 2008
18. Fujii-Kuriyama Y, Mimura J: Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes. Biochem Biophys Res Commun 338: 311-317, 2005 (Pubitemid 41540572)
19. Wu L, Whitlock JP Jr: Mechanism of dioxin action: Receptor-enhancer interactions in intact cells. Nucleic Acids Res 21: 119-125, 1993 (Pubitemid 23146301)
20. Nioi P, Hayes JD: Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res 555: 149-171, 2004 (Pubitemid 39359178)
21. Denison MS, Nagy SR: Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43: 309-334, 2003
22. Agarwal R: Effects of statins on renal function. Mayo Clin Proc 82: 1381-1390, 2007
23. Kawano H, Yano K: Pravastatin decreases blood pressure in hypertensive and hypercholesterolemic patients receiving antihypertensive treatment. Circ J 70: 1116-1121, 2006 (Pubitemid 44386989)
24. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH: Reduction in blood pressure with statins: Results from the UCSD Statin Study, a randomized trial. Arch Intern Med 168: 721-727, 2008
25. Yin QF, Xiong Y: Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol 45: 525-532, 2005 (Pubitemid 40734572)
26. Cohen BD: Methyl group deficiency and guanidino production in uremia. Mol Cell Biochem 244: 31-36, 2003
27. Watanabe K, Katsuhara M, Nakao H, Sato M: Detection and molecular analysis of plant- and insect-associated bacteria harboring aconitate isomerase involved in biosynthesis of trans-aconitic acid as antifeedant in brown planthoppers. Curr Microbiol 35: 97-102, 1997 (Pubitemid 27300769)
28. Tong WH, Rouault TA: Metabolic regulation of citrate and iron by aconitases: Role of iron-sulfur cluster biogenesis. Biometals 20: 549-564, 2007
29. Campese VM, Park J: HMG-CoA reductase inhibitors and the kidney. Kidney Int 71: 1215-1222, 2007
30. Oguz A, Uzunlulu M: Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 49: 303-311, 2008
31. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ: Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279: 23847-23850, 2004
32. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR: Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: Results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol 71: 1475-1486, 2007 (Pubitemid 47010900)
33. Bain MA, Faull R, Fornasini G, Milne RW, Evans AM: Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant 21: 1300-1304, 2006
34. Ceballos I, Chauveau P, Guerin V, Bardet J, Parvy P, Kamoun P, Jungers P: Early alterations of plasma free amino acids in chronic renal failure. Clin Chim Acta 188: 101-108, 1990 (Pubitemid 20150115)
35. McGregor DO, Dellow WJ, Lever M, George PM, Robson RA, Chambers ST: Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int 59: 2267-2272, 2001 (Pubitemid 32467620)
36. Kand'ar R, Zakova P: Allantoin as a marker of oxidative stress in human erythrocytes. Clin Chem Lab Med 46: 1270-1274, 2008
37. Reddy V, Bhandari S, Seymour AM: Myocardial function, energy provision, and carnitine deficiency in experimental uremia. J Am Soc Nephrol 18: 84-92, 2007 (Pubitemid 46070145)
38. Swendseid ME, Wang M, Vyhmeister I, Chan W, Siassi F, Tam CF, Kopple JD: Amino acid metabolism in the chronically uremic rat. Clin Nephrol 3: 240-246, 1975
39. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120: 1689-1699, 2001 (Pubitemid 32523487)
40. Watanabe T, Tan N, Saiki Y, Makisumi T, Nakamura S: Possible involvement of glucocorticoids in the modulation of interleukin-1-induced cardiovascular responses in rats. J Physiol 491: 231-239, 1996 (Pubitemid 26059564)
41. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shinozaki T, Kagaya Y, Shimokawa H: Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol 51: 317-326, 2008
42. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S: Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 50: 927-937, 2007 (Pubitemid 350130278)
43. Bindokas VP, Jordan J, Lee CC, Miller RJ: Superoxide production in rat hippocampal neurons: Selective imaging with hydroethidine. J Neurosci 16: 1324-1336, 1996 (Pubitemid 26145913)
44. Wang S, Hankinson O: Functional involvement of the Brahma/SWI2-related gene 1 protein in cytochrome P4501A1 transcription mediated by the aryl hydrocarbon receptor complex. J Biol Chem 277: 11821-11827, 2002 (Pubitemid 34952737)